Participant flow

Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3) · Source last updated 2023-06-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Taken orally twice daily (continuous 28 day treatment cycles)

   id

   FG000

   title

   Rucaparib 600 mg Tablets

2. description

   Taken orally twice daily (continuous 28 day treatment cycles)

   id

   FG001

   title

   Placebo Tablets

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         375

      2. group Id

         FG001

         num Subjects

         189

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         375

      2. group Id

         FG001

         num Subjects

         189

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

recruitment Details

564 subjects were recruited from 87 sites across 11 countries and randomized (2:1) to treatment with rucaparib or placebo

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice